Strong toxicity amyloid oligomers and uses thereof

• Main Authors: YU XIAOLIN, LIU RUITIAN, HUANG YARU, XIE XIXIU
• Format: Patent
• Language: Chinese; English
• Published: 23.02.2024
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to a novel highly toxic amyloid oligomer A [beta] o * 3F specifically bound to a 3F antibody, present in the cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived Mild Cognitive Impairment (MCI) patients, with levels exhibiting a very significant difference in CSF, blood and/or brain of AD patients, MCI patients and healthy elderly people, which is a highly toxic oligomer, and uses thereof. The compound is the most important toxic component in an A beta oligomer mixture, has a strong pathogenic effect, and plays a key role in generation and development of AD (Alzheimer's disease). The A [beta] o * 3F provides a new therapeutic and/or prophylactic and diagnostic target and a new therapeutic and/or prophylactic and diagnostic approach for AD. 本发明涉及新的强毒性淀粉样蛋白寡聚体Aβo*3F及其用途，所述Aβo*3F被3F抗体特异性结合，存在于AD患者和AD源性轻度认知障碍(MCI)患者的脑脊液(CSF)、血液和/或脑组织中，且水平在AD患者、MCI患者和健康老年人的CSF、血液和/或脑中呈现极显著差别，为超强毒性寡聚体，是Aβ寡聚体混合物中最主要的毒性成分，具有强烈的致病作用，在AD的发生和发展中起着关键作用。Aβo*3F为AD提供了新的治疗和/或预防、诊断靶点